A panel of experts examines unmet needs in the adoption of bispecific antibody therapy, emphasizing the importance of access and education for diverse stakeholders in oncology care to improve patient outcomes.
Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.
Experts discuss strategies to reduce treatment-related toxicities in bispecific antibody treatments, emphasizing clarity on dosing, hydration, and safety concerns.
Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.
Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.